Presentación
NEUROPROTECTIVE STRATEGIES IN NEURODEGENERATIVE DISEASES

enfermedadesneurodegenerativas@idipaz.es
Excellence Group
Composition
Name
Position
Institution
 
Antonio Cuadrado Pastor
Catedrático. Facultad de Medicina
Universidad Autónoma de Madrid
María Antón Valadés
Investigadora Predoctoral
Universidad Autónoma de Madrid
María Isabel Escoll Guerrero
Investigadora Postdoctoral
Universidad Autónoma de Madrid
Raquel Fernández Ginés
Investigadora Predoctoral
Universidad Autónoma de Madrid
Ángel Juan García Yagüe
Investigador Postdoctoral
CIBERNED
Nadia Giselle Innamorato
Investigadora Predoctoral
Universidad Autónoma de Madrid
Diego Lastra Martínez
Investigador Predoctoral
Universidad Autónoma de Madrid
Ángela Martínez Valverde
Investigadora Postdoctoral. CSIC
IIB "Alberto Sols"
Patricia Rada Llano
Investigadora Postdoctoral
IIB "Alberto Sols"
Natalia Robledinos Antón
Investigador Predoctoral
Universidad Autónoma de Madrid
Ana Isabel Rojo Sanchís
Profesora Ayudante Doctor
Universidad Autónoma de Madrid
Strategic Objective
Oxidative stress is a key element in the aetiopathogenesis of neurodegenerative diseases and their co-morbidities. Our laboratory studies the antioxidant protection mechanisms activated by extracellular signals and how this response ould be regulated pharmacologically to provide a therapeutic benefit in these diseases.
To meet these two objectives, we are studying signalling pathways that regulate antioxidant metabolism and provide a general protective response. An important finding of this group was the observation that the PI3K/AKT/GSK-3 survival pathway regulates the transcription factor Nrf2, guardian of cellular redox homeostasis, that provides protection against oxidative, inflammatory and proteotoxic stress. For the past year we have been working on the validation this transcription factor as a new therapeutic target to modify progression of Parkinson’s and Alzheimer’s disease as well as co-morbid retinopathy and type II diabetes.
Research Lines
• Role of oxidative stress in neuronal death and neuroinflammation in neurodegenerative diseases.
• The transcription factor Nrf2 as a new therapeutic target in Parkinson’s and Alzheimer’s disease.
• Molecular basis of type 2 diabetes and its complications (diabetic retinopathy and nephropathy).